Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lenalidomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 13/20 | 1.00 |
| ▸ | DDB1 known ✓ | Q16531 | 3/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 1.00 |
| ▸ | IKZF1 | Q13422 | 3/20 | 1.00 |
| ▸ | TNF | P01375 | 3/20 | 1.00 |
| ▸ | IL1B | P01584 | 3/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.53 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenalidomide SCHEMBL32978 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL30876939 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL17999103 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL18825 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192655 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL868339 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL29414335 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192663 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192650 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL18917500 | 0.99 | CRBN (0.97) | CRBNIKZF3IKZF1DDB1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| US-20260109777-A1 | METHODS OF TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB AS A MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE | GENENTECH INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4713368-A1 | ANTI-CD28 ANTIBODIES AND METHODS RELATED THERETO | Adimab, LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250353916-A1 | TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2025-11-20 | — | — | US | disclosed |
| EP-4633664-A2 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR BAFF-R AND CD19 AND METHODS AND USES THEREOF | Juno Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250236671-A1 | CD229 Car T Cells And Methods Of Use Thereof | UNIV UTAH RES FOUND (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4565262-A2 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR GPRC5D AND BCMA | Juno Therapeutics, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119925616-A | CD20 therapy, CD22 therapy and combination therapy with CD19 Chimeric Antigen Receptor (CAR) expressing cells | 诺华股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-110461315-B | Treatment and prevention of cytokine release syndrome using chimeric antigen receptor in combination with kinase inhibitors | 诺华股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4543923-A1 | TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS | Juno Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4043485-A1 | CD28 COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| CN-114621969-A | Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy | 诺华股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2022104061-A1 | COMBINATION THERAPIES WITH CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELLS | NOVARTIS AG (CH) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022098638-A2 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES | GENENTECH, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022098648-A2 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022098628-A2 | SUBCUTANEOUS DOSING OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES | GENENTECH, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| EP-3280729-B1 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) - EXPRESSING CELL | NOVARTIS AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3967709-A1 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | Novartis AG (CH) | 2022-03-16 | — | — | EP | disclosed |
| US-20220040263-A1 | COMPANION DIAGNOSTIC FOR COMBINATION LENALIDOMIDE AND ERYTHROPOIETIN TREATMENT | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353916-A1 | TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR | CD2, FCGR3B, CD58 | CRBN 889/4885DDB1 2912/4885IKZF3 74/4885 |
| US-20260109777-A1 | METHODS OF TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB AS A MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE | BCL6, BCL6B, MALT1 | CRBN 152/4885DDB1 1336/4885IKZF3 613/4885 |
| US-20220040263-A1 | COMPANION DIAGNOSTIC FOR COMBINATION LENALIDOMIDE AND ERYTHROPOIETIN TREATMENT | EPOR, IL15RA, PTPRE | CRBN 247/4885DDB1 2092/4885IKZF3 1218/4885 |
| US-20250236671-A1 | CD229 Car T Cells And Methods Of Use Thereof | CD2, CD2BP2, CD22 | CRBN 853/4885DDB1 361/4885IKZF3 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.